Most Read Articles
2 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 2 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
3 days ago
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.

Neoadjuvant chemotherapy not linked to perioperative surgical morbidity

27 Dec 2019

The last decade has seen a significant increase in the use of neoadjuvant chemotherapy for nonmetastatic muscle invasive urothelial bladder cancer, and a recent study has shown that its utilization is not associated with adverse perioperative outcome following robot-assisted radical cystectomy.

The International Robotic Cystectomy Consortium database was retrospectively reviewed between 2006 and 2017. Patients with nonmuscle invasive bladder cancer were excluded, and those eligible for the study were divided into two groups: those who did vs did not receive neoadjuvant chemotherapy. Data were reviewed for demographics, preoperative, operative and 90-day perioperative outcomes.

Trends of neoadjuvant chemotherapy associations with high-grade and overall complications with time were evaluated using the Cochran-Armitage trend test. The authors also carried out multivariate stepwise regression analyses to determine whether neoadjuvant chemotherapy was associated with prolonged operative time, 90-day postoperative complications, readmissions, reoperations and mortality after robot-assisted radical cystectomy.

Neoadjuvant chemotherapy was given to a total of 298 patients (26 percent), who apparently were younger (age, 67 vs 69 years; p=0.01) and more frequently had an American Society Anesthesiologists score of 3 (62 percent vs 55 percent; p=0.02) and pathological T3 stage or greater disease (28 percent vs 22 percent; p=0.04).

Neoadjuvant chemotherapy utilization significantly increased from 10 percent in 2006–2007 to 42 percent in 2016–2017 (p<0.01).

Multivariate analysis revealed that neoadjuvant chemotherapy was not significantly associated with prolonged operative time, hospital stay, 90-day postoperative complications, reoperation or mortality. However, it correlated with 90-day readmissions following robot-assisted radical cystectomy (odds ratio, 5.90, 95 percent confidence interval, 3.30–10.90; p<0.01).

Editor's Recommendations
Most Read Articles
2 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 2 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
3 days ago
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.